DOI 10.1016/j.jare.2026.08.033
A biparatopic antibody targeting the Cε2 and Cε3 domains of IgE disrupts IgE-FcεRI interaction.
Аннотация
INTRODUCTION
Therapeutic anti-IgE antibodies that block the interaction between immunoglobulin E (IgE) and its high-affinity receptor (FcεRI) have been a popular direction for the treatment of allergic diseases.
OBJECTIVES
Although both the Cε2 and Cε3 domains of IgE play important roles in stabilizing the IgE:FcεRI complex, most of those anti-IgE antibodies target only the Cε3 domain of IgE. Here, we develop a biparatopic antibody (SA25-A4-IgG1Fc) targeting both the Cε2 and Cε3 domains of IgE, which disrupts IgE-FcεRI interaction.
METHODS
We link nanobody A4 and SA25 by a (GGGGS)4 linker, and fuse with a human IgG1Fc tag to generate SA25-A4-IgG1Fc. The FcεRI disruption effect of SA25-A4-IgG1Fc is tested by enzyme-linked immunosorbent assay, flow cytometry, surface plasmon resonance, and food allergic humanized mice.
RESULTS
We identify an alpaca nanobody A4, which recognizes the Cε2 domain of IgE with nanomolar affinity, and a shark nanobody SA25, which binds the Cε3 domain of IgE competitively with FcεRⅠ. Targeting both the Cε2 and Cε3 domains of IgE, the biparatopic antibody (SA25-A4-IgG1Fc) binds to IgE with picomolar affinity, and blocks IgE-FcεRI interaction with greater potency than omalizumab in vitro. In addition, SA25-A4-IgG1Fc also removes IgE from human basophils and mast cells with high efficacy, and inhibits ovalbumin (OVA)-induced IgE-dependent food allergy in IgE/FcεRⅠ humanized mice in vivo.
CONCLUSION
Our results demonstrate that the biparatopic antibody SA25-A4-IgG1Fc is a promising inhibitor for the treatment of food allergy, and provide a novel idea for the development of anti-IgE antibodies.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.